All articles by Pradeep Bairaboina

Pradeep Bairaboina

Recipharm and PLG announce strategic partnership to accelerate development projects

The two companies will ensure customers receive comprehensive support from early-stage development to approval and market access

Daiichi Sankyo seeks approval for Enhertu in Japan for HER2 positive tumours

The New Drug Application focuses on treating adult patients with HER2 positive advanced or recurrent solid tumours that do not respond to or cannot tolerate existing standard treatments

Thermo Fisher to invest $2bn to strengthen US healthcare supply chain

The investment plan includes $1.5bn for expanding and upgrading US manufacturing facilities, along with $500m directed towards R&D focused on high-impact innovations

Granite Bio secures $100m funding to advance autoimmune disease treatments

The financing includes a $30m Series A round, led by founding investors Versant Ventures and Novartis Venture Fund, and a $70m Series B round, led by Forbion and Sanofi Ventures

Guardant Health announces strategic collaboration with Pfizer  

Multi-year global collaboration will utilize Guardant liquid biopsy portfolio in research and clinical applications and evaluate utility of ctDNA for monitoring therapy response

US FDA approves argenx’s prefilled syringe for neurological conditions

The prefilled syringe includes efgartigimod alfa and hyaluronidase-qvfc and can be administered subcutaneously in 20 to 30 seconds by patients, caregivers, or healthcare providers

Trump administration’s FDA cuts may delay new medicine reviews

The move, which is part of a broader initiative by President Donald Trump to reduce the federal workforce, could potentially hinder efforts to expedite the availability of promising treatments

J&J gets EC nod for expanded use of daratumumab in multiple myeloma

The latest approval allows the use of daratumumab in combination with bortezomib, lenalidomide, and dexamethasone (daratumumab-VRd) for treating adults newly diagnosed with multiple myeloma

Teva announces FDA filing acceptance for AJOVY (fremanezumab) in pediatric episodic migraine prevention

If approved for an expanded pediatric indication, AJOVY would be the first calcitonin gene-related peptide (CGRP) antagonist for migraine prevention in adults and episodic migraine prevention in pediatric patients, addressing the high unmet need for effective treatments

Meitheal Pharmaceuticals launches FDA-approved liraglutide injection in US

The liraglutide injection is intended to aid glycemic control in adults and children aged 10 and above with type 2 diabetes mellitus, in conjunction with diet and exercise